1383935-72-5

Upstream product

• 162119-25-7 (1S,2S,3S,4R,5R)-2,3,4-tris(benzyloxy)-5-[(benzyloxy)methyl]cyclohexanol 
• 124330-57-0 (2R,3S,4R,5R)-2,3,4-tris(benzyloxy)-5-[(benzyloxy)methyl]cyclohexanone 
• 6793-92-6 p-benzyloxyphenylbromide 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 1383935-73-6 4-{3-[(3aS,4S,5aR,9aR,9bR)-2,2,8,8-tetramethylhexahydro-3aH-[1,3]dioxolo[4',5':5,6]benzo[1,2-d][1,3]dioxin-4-yl]benzyl}phenyl trifluoromethanesulfonate 
• 1383935-74-7 (3aS,4S,5aR,9aR,9bR)-4-[3-(4-cyclopropylbenzyl)phenyl]-2,2,8,8-tetramethylhexahydro-3aH-[1,3]dioxolo[4',5':5,6]benzo[1,2-d][1,3]dioxin 

Relevant academic research and scientific papers

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

C-Aryl 5a-carba-β-d-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high h

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.